These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36111579)

  • 1. SGLT2 inhibitors protect cardiomyocytes from myocardial infarction: a direct mechanism?
    Zhang J; Zhang F; Ge J
    Future Cardiol; 2022 Nov; 18(11):867-882. PubMed ID: 36111579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.
    Jiang K; Xu Y; Wang D; Chen F; Tu Z; Qian J; Xu S; Xu Y; Hwa J; Li J; Shang H; Xiang Y
    Protein Cell; 2022 May; 13(5):336-359. PubMed ID: 33417139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
    Wu VC; Li YR; Wang CY
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.
    Lee TM; Chang NC; Lin SZ
    Free Radic Biol Med; 2017 Mar; 104():298-310. PubMed ID: 28132924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy.
    Gao Z; Bao J; Hu Y; Tu J; Ye L; Wang L
    Curr Drug Targets; 2023; 24(13):1009-1022. PubMed ID: 37691190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors; suggested mechanism of actions in supporting post-myocardial infarction patients.
    Cotton M; Hawley A
    Future Cardiol; 2023 Jul; 19(9):419-422. PubMed ID: 37702265
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
    Filippatos TD; Liontos A; Papakitsou I; Elisaf MS
    Postgrad Med; 2019 Mar; 131(2):82-88. PubMed ID: 30757937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
    Woo VC
    Can J Diabetes; 2020 Feb; 44(1):61-67. PubMed ID: 31839265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
    Mizuno M; Kuno A; Yano T; Miki T; Oshima H; Sato T; Nakata K; Kimura Y; Tanno M; Miura T
    Physiol Rep; 2018 Jun; 6(12):e13741. PubMed ID: 29932506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
    Perry RJ; Shulman GI
    J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.